BioCentury
ARTICLE | Financial News

Argos raises $45 million in IPO

February 8, 2014 1:14 AM UTC

Argos Therapeutics Inc. (NASDAQ:ARGS) raised $45 million through the sale of a bumped-up number of shares below its proposed price range in an IPO. The company sold 5.6 million shares at $8, which values the cancer company at $152.4 million. Last month, Argos said it planned to sell 4.3 million shares at $13-$15. Piper Jaffray; Stifel; JMP Securities; and Needham are underwriters. Argos' AGS-003 is in the Phase III ADAPT trial to treat metastatic renal cell carcinoma (RCC). AGS-003 is a second-generation RNA-loaded autologous dendritic cell immunotherapy. ...